Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK0529 in Infants Hospitalized With RSV
NCT02460016Phase 1Terminated
- Sponsor
- Ark Biosciences
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ziresovir in respiratory syncytial virus infection (RSV), sponsored by Ark Biosciences. Primary endpoint: Number of Adverse Events. Started Aug 2015; status: terminated.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02460016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460016.